OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M Turnover 18.46%
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+7.52%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$126M
AUM Growth
+$6.95M
Cap. Flow
-$1.04M
Cap. Flow %
-0.83%
Top 10 Hldgs %
37.72%
Holding
74
New
9
Increased
25
Reduced
7
Closed
17
Avg Time Held Equity + Options
0.4 years
Top 10 Avg Time Held Equity + Options
0.2 years
Top 20 Avg Time Held Equity + Options
0.4 years
Avg Time Held Equity only
0.4 years
Top 10 Avg Time Held Equity only
0.2 years
Top 20 Avg Time Held Equity only
0.4 years

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$3.42M
2
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$1.55M
3
INFI
Infinity Pharmaceuticals, Inc.
INFI
+$1.03M
4
PCRX icon
Pacira BioSciences
PCRX
+$949K
5
ARRY icon
Array Biopharma Inc
ARRY
+$886K

Top Sells

Rank Stock Value
1
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$4.15M
2
PCYC
PHARMACYCLICS INC
PCYC
+$3.48M
3
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$1.73M
4
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$912K
5
TENX icon
Tenax Therapeutics
TENX
+$812K

Sector Composition

Rank Sector Weight
1 Healthcare 82.86%
2 Miscellaneous 16.89%
3 Financials 0.25%
4 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
TSRO
26
DELISTED
TESARO, Inc.
TSRO
$1.76M 1.4%
30,000
+10,000
+50% +$574K
2015 Q1
1 quarter
EPZM
27
DELISTED
Epizyme, Inc
EPZM
$1.74M 1.38%
72,379
+24,040
+50% +$463K
2014 Q4
2 quarters
XBI icon
28
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.72B
$1.35M 1.07%
+3,000
New +$233K
2015 Q2
0 quarters
VCEL icon
29
Vericel Corp
VCEL
$2.06B
$1.29M 1.02%
362,157
– –
2014 Q4
2 quarters
ASMB icon
30
Assembly Biosciences
ASMB
$416M
$1.25M 0.99%
5,417
– –
2015 Q1
1 quarter
ESPR icon
31
DELISTED
Esperion Therapeutics
ESPR
$1.23M 0.97%
15,000
– –
2015 Q1
1 quarter
AVDL
32
DELISTED
Avadel Pharmaceuticals
AVDL
$1.1M 0.87%
51,788
+10,000
+24% +$179K
2014 Q4
2 quarters
UTHR icon
33
United Therapeutics
UTHR
$23.2B
$939K 0.74%
5,399
+186
+4% +$33.5K
2014 Q4
2 quarters
NSTG
34
DELISTED
NanoString Technologies, Inc.
NSTG
$925K 0.73%
+60,000
New +$802K
2015 Q2
0 quarters
RARE icon
35
Ultragenyx Pharmaceutical
RARE
$1.48B
$922K 0.73%
9,000
-3,000
-25% -$233K
2015 Q1
1 quarter
MACK icon
36
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$890K 0.7%
9,152
– –
2014 Q4
2 quarters
CMRX icon
37
DELISTED
Chimerix, Inc.
CMRX
$885K 0.7%
19,152
– –
2014 Q4
2 quarters
STML
38
DELISTED
Stemline Therapeutics, Inc.
STML
$883K 0.7%
75,000
– –
2014 Q4
2 quarters
INFI
39
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$876K 0.69%
+80,000
New +$1.03M
2015 Q2
0 quarters
AMGN icon
40
Amgen
AMGN
$231B
$852K 0.67%
5,550
+612
+12% +$98K
2014 Q4
2 quarters
XNPT
41
DELISTED
XENOPORT, INC.
XNPT
$797K 0.63%
130,000
– –
2014 Q4
2 quarters
CRIS icon
42
Curis
CRIS
$1.44M
$712K 0.56%
+108
New +$649K
2015 Q2
0 quarters
OCRX
43
DELISTED
Ocera Therapeutics, Inc.
OCRX
$709K 0.56%
186,573
+3,900
+2% +$15K
2014 Q4
2 quarters
ALBO
44
DELISTED
Albireo Pharma Inc
ALBO
$670K 0.53%
+21,667
New +$728K
2015 Q2
0 quarters
RLYP
45
DELISTED
RELYPSA INC COM
RLYP
$596K 0.47%
18,000
– –
2015 Q1
1 quarter
ACHN
46
DELISTED
Achillion Pharmaceuticals
ACHN
$591K 0.47%
66,704
– –
2014 Q4
2 quarters
ARWR icon
47
Arrowhead Research
ARWR
$8.35B
$587K 0.46%
82,133
– –
2014 Q4
2 quarters
ZGNX
48
DELISTED
Zogenix, Inc.
ZGNX
$504K 0.4%
37,500
– –
2015 Q1
1 quarter
GILD icon
49
Gilead Sciences
GILD
$190B
$496K 0.39%
4,234
+583
+16% +$63.7K
2014 Q4
2 quarters
TLPH icon
50
Talphera
TLPH
$55M
$424K 0.34%
4,998
– –
2014 Q4
2 quarters
1
2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q2 2015 Portfolio in Review

As of Q2 2015, Opus Point Partners Management held 74 positions worth $126M, up 5.8% from $119M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Opus Point Partners Management's Q2 2015 filing shows 9 new, 25 increased, 7 reduced and 17 closed positions. Its largest new stake was AstraZeneca: 50,000 shares worth $3.19M. The largest sale was SALIX PHARMACEUTICALS LTD DEL, an estimated $4.15M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 78% a quarter earlier, followed by Miscellaneous and Financials.

  • Opus Point Partners Management's largest Q2 2015 buy was AstraZeneca: 50,000 shares worth $3.19M.
  • Opus Point Partners Management added most to ProShares Ultra NASDAQ Biotechnology in Q2 2015, an estimated $1.55M increase.
  • Opus Point Partners Management's biggest Q2 2015 reduction was Clovis Oncology, Inc., cutting an estimated $307K.
  • Opus Point Partners Management fully exited SALIX PHARMACEUTICALS LTD DEL in Q2 2015, selling an estimated $4.15M.
  • Opus Point Partners Management's ten largest holdings make up 38% of its $126M portfolio in Q2 2015.
  • Opus Point Partners Management opened 9 new positions and closed 17 in Q2 2015.
  • Opus Point Partners Management's portfolio value rose 5.8% quarter-over-quarter to $126M.

Based on Opus Point Partners Management's 13F filing for Q2 2015, filed 14 Aug 2015.